RISEN PHARMA

Development Philosophy People-centered, innovation-driven, strive for enterprising

Make important contributions to the anti-aging and anti-tumor medical areas for healthier and longer human lives

Risen Pharma

A clinical stage group with innovative drug research and development capability and international competitiveness

Committed to clinical urgent, patient accessible drug R&D and commercialization. The Group has two R&D centers (with a total square footage of nearly 9000m²), which are located in the hub of Shanghai Zhangjiang Hi-Tech Park and Suzhou Industrial Park, and invested in the construction of a manufacturing site covering 55 acres of land in the Life Blue Bay of Lingang,. The Group has nearly 20 new drug research and development pipelines, focusing on drug R&D in the three core therapeutic areas of orthopedics, oncology and neuroscience, and dedicated R&D investment in the field of siRNA.

Small Molecule Drugs

Based on decades of accumulation in scientific research, keep innovating, and commit to "First-in-class" and "Best-in-class" small molecule drug research and development.

siRNA Drugs

Rooted in a solid biomedical foundation, focusing on siRNA drug discovery and development, and striving to create the next-generation therapeutics.

Combo Therapies

To exert the synergistic effect of drugs in combo therapies, working extensively with TopAlliance, and jointly developing the potential of combo therapies from both companies' pipelines.

Core Competitiveness

Product pipeline

Focuses on source innovation, with a nearly 20 new drug R&D pipelines. Among them, projects for osteoarthritis, Alzheimer's disease, and tumor treatment are in different clinical trial stages in China and the US. Several pre-clinical pipelines have been built in the field of siRNA drug discovery and development.

Translational medicine.

Jointly establish a top-notch translational medicine platform with TopAlliance, to rapidly translate cutting-edge science and clinical information into discovery projects. Conduct in-depth research on the mechanism of action of drugs, discover biomarkers, and explore the synergistic effects of combination therapies to significantly improve the efficiency of clinical development.

Peer-leading R&D center, integrating functions of target validation, protein structure analysis, high-throughput screening, drug design and synthesis, DMPK, in vivo efficacy and toxicology, CMC research, and translational medicine into a comprehensive drug discovery and development platform.

NEWS

PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.

Risen Pharma and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.

Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.

Risen's innovative KRAS drug research result has been selected for presentation at the AACR Annual Meeting 2024 in San Diego, California!

Risen found status in the "2023 Hurun Global Cheetah Enterprise List"

Congratulations! Risen successfully acquired Biosafety Laboratory level 2 (BSL-2) qualification.

Congratulations! Risen laned in “KPMG China Biotech Future Sector 50 Ranking”

Congratulations! Risen was entitled as a "special and innovative" small to medium-sized enterprise in Shanghai

First in China: ANGPTL3 siRNA drug developed Risen and TopAlliance jointly approved for clinical trial.

Congratulations! Risen successfully acquired the identification as the national high-tech enterprise!

Risen signed a strategic cooperation agreement with China Merchants Bank Shanghai Branch

Shanghai Zhangjiang R&D Center.

Suzhou Industrial Park R&D Center.

Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb